Clinical Trial Update: Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and safety study of LY03004 in stable schizophrenia or schizoaffective disorder patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• LY03004

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 1 | Status: COMPLETED